文献速递前列腺癌膀胱癌与上尿路尿路上皮癌

cT4期前列腺癌患者根治性膀胱切除术的结局预测因素:一项62例患者的多机构研究

Outcome predictors of radical cystectomy in patients with cT4 prostate cancer: a multi-institutional study of 62 patients.
PubMed 文献 · BJU Int · 2017-03-26

该多机构研究评估了1972至2011年间62例接受根治性膀胱切除加盆腔淋巴结清扫的cT4cN0-1cM0前列腺癌患者,分析生存结局及预测因素。中位随访期间19例(30.6%)无临床进展,无精囊侵犯患者10年前列腺癌特异性生存率为75%,而精囊侵犯患者为24%。作者认为根治性膀胱切除术可作为cT4前列腺癌局部控制及多模式治疗的一部分。

要点

  • 62例cT4cN0-1cM0前列腺癌患者接受根治性膀胱切除加盆腔淋巴结清扫。
  • 无精囊侵犯者10年前列腺癌特异性生存率75%,精囊侵犯者为24%。
  • 无精囊侵犯患者结局最佳,精囊侵犯者进展风险更高,可能需要更积极的全身治疗。

核心结论

  • 对于cT4前列腺癌,根治性膀胱切除术可作为局部控制的适当治疗,并作为多模式治疗方法的一部分。
  • 复发虽有可能,但不一定转化为癌症特异性死亡。
  • 无精囊侵犯的男性10年前列腺癌特异性生存率为75%。
  • 精囊侵犯患者结局较差,但局部控制可能良好;然而这些患者进展风险更高,可能需要更积极的全身治疗。

研究设计与样本

  • 多机构研究,评估1972至2011年间接受根治性膀胱切除加盆腔淋巴结清扫的62例cT4cN0-1cM0前列腺癌患者。
  • 采用描述性统计、Kaplan-Meier法和log-rank检验描绘生存率。
  • 采用单变量和多变量Cox回归分析检验预测因素与无进展生存、前列腺癌特异性生存和总生存之间的关联。

主要发现

  • 62例患者中,19例(30.6%)随访期间无临床进展,2例(3.2%)出现局部复发,32例(51.6%)出现血行转移,9例(14.5%)出现盆腔和远处联合转移。
  • 40例(64.5%)死亡,其中34例(54.8%)死于前列腺癌,6例(9.7%)死于其他原因。
  • 末次随访时无转移的19例患者中位生存时间为86个月(范围1-314个月),其中8/19例随访超过5年,5例无转移生存超过15年。
  • 无精囊侵犯患者结局最佳,估计10年前列腺癌特异性生存率为75%,而精囊侵犯患者为24%。

临床怎么用

  • 对于cT4前列腺癌,根治性膀胱切除术可作为局部控制的适当治疗,并作为多模式治疗方法的一部分。
  • 无精囊侵犯的男性10年前列腺癌特异性生存率为75%。
  • 精囊侵犯患者进展风险更高,可能需要更积极的全身治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To identify which patients with macroscopic bladder-infiltrating T4 prostate cancer (PCa) might have favourable outcomes when treated with radical cystectomy (RC). MATERIALS AND METHODS: We evaluated 62 patients with cT4cN0-1 cM0 PCa treated with RC and pelvic lymph node dissection between 1972 and 2011. In addition to descriptive statistics, the Kaplan-Meier method and log-rank tests were used to depict survival rates. Univariate and multivariate Cox regression analysis tested the association between predictors and progression-free, PCa-specific and overall survival. RESULTS: Of the 62 patients, 19 (30.6%) did not have clinical progression during follow-up, two (3.2%) had local recurrence, and 32 (51.6%) had haematogenous and nine (14.5%) combined pelvic and distant metastasis. Forty patients (64.5%) died, 34 (54.8%) from PCa and six (9.7%) from other causes. The median (range) survival time of the 19 patients who were metastasis-free at last follow-up was 86 (1-314) months, 8/19 patients had a follow-up of >5 years, and five patients survived metastasis-free for >15 years. Patients without seminal vesicle invasion (SVI) had the best outcomes, with an estimated 10-year PCa-specific survival of 75% compared with 24% for patients with SVI. CONCLUSION: For cT4 PCa RC can be an appropriate treatment for local control and part of a multimodality-treatment approach. Although recurrences are probable, these do not necessarily translate into cancer-specific death. Men without SVI had a 75% 10-year PCa-specific survival. Although outcomes for patients with SVI are not as favourable, there can be good local control; however, these patients are at higher risk of progression and may need more aggressive systemic treatment.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Spahn M, Morlacco A, Boxler S, et al. Outcome predictors of radical cystectomy in patients with cT4 prostate cancer: a multi-institutional study of 62 patients. BJU Int. 2017. PMID: 28220605. doi:10.1111/bju.13818

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。